抗磷脂综合征患者颈动脉与股动脉粥样硬化:病例对照研究中与糖尿病风险相当
该病例对照研究纳入86例血栓性抗磷脂综合征(APS)患者、86例糖尿病(DM)患者和86名健康对照,年龄和性别个体匹配,超声评估颈动脉和股动脉亚临床粥样硬化。APS患者动脉粥样硬化斑块风险约为健康对照的2.5倍,与DM患者相近;斑块与APS患者传统心血管病危险因素数量相关,在SLE/APS中还与IgG抗β2糖蛋白I抗体相关。
要点
- 血栓性APS患者颈动脉和股动脉粥样硬化斑块风险约为健康对照的2.5倍,与DM患者相近。
- APS患者斑块与统心血管病危险因素数量相关(PAPS RR=2.75,SLE/APS RR=1.84,均p<0.001)。
- SLE/APS患者斑块还与IgG抗β2糖蛋白I抗体相关。
核心结论
- 原发性APS和SLE相关APS患者颈动脉和股动脉粥样硬化斑块风险约为健康对照的2.5倍,与糖尿病患者相近。
- APS和SLE/APS患者斑块与统心血管病危险因素数量相关,SLE/APS患者斑块还与IgG抗β2糖蛋白I抗体相关。
研究设计与样本
- 病例对照研究,纳入86例血栓性APS患者(43例原发性APS,43例SLE相关APS)、86例糖尿病患者和86名健康对照,按年龄和性别个体匹配。
- 采用超声评估颈动脉和股动脉亚临床粥样硬化标志物,并分析其与APS传统及疾病相关因素的关系。
主要发现
- 颈动脉斑块见于28%的原发性APS、23%的SLE/APS、30%的糖尿病患者,对照组为9%(p=0.006)。
- 股动脉斑块见于33%的原发性APS、19%的SLE/APS、20%的糖尿病患者,对照组为9%(p=0.032)。
- 多因素回归校正年龄、性别、高血压、血脂异常、吸烟、BMI和冠心病家族史后,任何部位粥样硬化斑块的相对风险估计值:原发性APS为2.72(p=0.004),SLE/APS为2.63(p=0.009),糖尿病为1.98(p=0.032)。
- APS患者中,斑块与统心血管病危险因素数量相关:原发性APS RR=2.75(p<0.001),SLE/APS RR=1.84(p<0.001)。
- SLE/APS患者中,斑块与IgG抗β2糖蛋白I抗体相关。
关键数值与推荐
- 颈动脉斑块患病率:原发性APS 28%,SLE/APS 23%,糖尿病30%,对照组9%(p=0.006)。
- 股动脉斑块患病率:原发性APS 33%,SLE/APS 19%,糖尿病20%,对照组9%(p=0.032)。
- 任何部位斑块多因素校正后相对风险:原发性APS 2.72(p=0.004),SLE/APS 2.63(p=0.009),糖尿病1.98(p=0.032)。
- APS患者斑块与统心血管病危险因素数量的关联:原发性APS RR=2.75(p<0.001),SLE/APS RR=1.84(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiphospholipid syndrome (APS) may carry a worse prognosis for vascular complications when co-existing with subclinical atherosclerosis; however, the association between the two conditions remains ambiguous. METHODS: We evaluated ultrasonographic markers of subclinical atherosclerosis in carotid and femoral arteries of 86 patients with thrombotic APS [43 primary APS (PAPS), 43 systemic lupus erythematosus-associated APS (SLE/APS)], 86 patients with diabetes mellitus (DM) and 86 healthy controls, individually matched for age and gender, and investigated their associations with traditional and disease-related factors in APS. RESULTS: Carotid plaques were found in 28% of PAPS, 23% of SLE/APS, and 30% of DM patients versus 9% of controls (p = 0.006). Femoral plaques were found in 33% of PAPS, 19% of SLE/APS, 20% of DM, and 9% of controls (p = 0.032). Multivariate regression-derived relative risk estimates for atherosclerotic plaques in any location were 2.72 for PAPS, 2.63 for SLE/APS, and 1.98 for DM (p = 0.004, 0.009, and 0.032 respectively), after adjusting for age, gender, hypertension, dyslipidemia, smoking, BMI, and family history of coronary disease. Among patients with APS, atherosclerotic plaques were associated with the number of traditional CVD risk factors in both PAPS (RR = 2.75, p < 0.001) and SLE/APS (RR = 1.84, p < 0.001), and with IgG anti-beta2-glycoprotein I antibodies in SLE/APS. CONCLUSIONS: Patients with PAPS and SLE/APS have a nearly 2.5-fold risk of atherosclerotic plaques in carotid and femoral arteries compared to healthy controls, similar to DM patients. Atherosclerotic plaques are associated with the number of traditional risk factors in both APS and SLE/APS, and with IgG anti-beta2-glycoprotein I antibodies in SLE/APS.
引用
- Kravvariti E, Konstantonis G, Tentolouris N, et al. Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. Semin Arthritis Rheum. 2017. PMID: 29150207. doi:10.1016/j.semarthrit.2017.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。